logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Misako Nagasaka

st marianna university school of medicine
H指数:40
被引数:7,023

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study

奥罗玛西布（olomorasib）对KRAS G12C突变型晚期实体瘤的泛瘤活性：一项首次人体研究

Nature Communications
IF15.7
2026-03-120
OAAI
Yonina R. Murciano-Goroff; Antoine Hollebecque; Rebecca S. Heist; Philippe A. Cassier; Ji-Youn Han; So Yeon Kim; Joshua K. Sabari; Diego Tosi; Adrian Sacher; Timothy F. Burns; Toshio Shimizu; Natraj Reddy Ammakkanavar; Alexander Spira; Carlos Gomez-Roca; Amita Patnaik; Rasha Cosman; J. Nicholas Bodor; Misako Nagasaka; Arthur Xintian You; Samuel C. McNeely; Raimund Peter; Aaron Fink; Aaron Chen; Geoffrey R. Oxnard; Melinda D. Willard; Yasutoshi Kuboki; Takafumi Koyama
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC A Multicenter Retrospective Study

继续使用下一代ALK TKIs联合化疗治疗晚期ALK阳性NSCLC的疗效与安全性：一项多中心回顾性研究

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
IF16.4
2025-12-010
PRE
Waliany, Sarah; Roy, Shambo Guha; Pecci, Federica; Weber, Urs M.; Sun, Fangdi; Arter, Zhaohui; Lomibao, Meghanne; V. Alessi, Joao; Nishino, Mizuki; Luo, Faustine; Repetto, Matteo; Falcon, Christina; Do, Andrew; Peterson, Jennifer; Liang, Joyce; Liu, Audrey; Nagasaka, Misako; Ricciuti, Biagio; Drilon, Alexander; Ou, S. Ignatius; Neal, Joel W.; Patil, Tejas; Awad, Mark; Yeap, Beow Y.; Digumarthy, Subba R.; Lin, Jessica J.
Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib

使用Gilteritinib成功并持续控制长期（>24个月）疾病，在一名有脑转移且对多种ALK TKIs耐药的<em>ALK+</em> NSCLC患者中的病例报告及Gilteritinib相关文献综述。

Lung Cancer: Targets and Therapy
IF0
2025-10-220
OAAI
Sai-Hong Ignatius Ou; Cathleen June Park; Zhaohui Liao Arter; Misako Nagasaka
Pembrolizumab in Combination With Platinum-Based Chemotherapy in Patients With Recurrent EGFR and ALK Gene Altered Non-Small-Cell Lung Cancer (NSCLC)

帕博利珠单抗联合铂类为基础的化疗在EGFR和ALK基因突变非小细胞肺癌（NSCLC）复发患者中的应用

Clinical Lung Cancer
IF3.3
2025-10-030
PRE
Shirish M. Gadgeel; Misako Nagasaka; Karen Dziubek; Thomas Braun; Khaled Hassan; Haiying Cheng; Balazs Halmos; Antoinette Wozniak; James Stevenson; Pradnya Patil; Nathan Pennell; Mary Jo Fidler; Angel Qin; Zeqi Niu; Sunitha Nagrath; Gregory P. Kalemkerian
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

肺大细胞神经内分泌癌的整合分子与临床特征分析

Nature Communications
IF15.7
2025-08-190
OA
Amin H. Nassar; Chul Kim; Tolulope Adeyelu; Elias Bou Farhat; Hassan Abushukair; Mehrdad Rakaee; Kelsey Matteson; Shun-Fat Lau; Yamato Takabe; Antonio Ocejo; Fatemeh Ardeshir-Larijani; Ticiana Leal; Suresh Ramalingam; Sumaiya Alam; Jhanelle E. Gray; James Hicks; David Kaldas; Javier Baena; Maria Zurera Berjaga; Frank Aboubakar Nana; Christian Grohe; Heike Leuders; Fabrizio Citarella; Alessio Cortellini; Emanuele Claudio Mingo; Danny Pancirer; Millie Das; Timothy John Ellis-Caleo; Justin M. Cheung; Jessica J. Lin; Alexander S. Watson; D. Ross Camidge; Arthi Sridhar; Kaushal Parikh; Fionnuala Crowley; Thomas U. Marron; Vanya Aggarwal; Murtaza Ahmed; Kamya Sankar; Hassan Kawtharany; Jun Zhang; Dwight H. Owen; Mingjia Li; Misako Nagasaka; David J. Pinato; Nichola Awosika; Khaled Alhamad; Sonam Puri; Unaiza Zaman; Divya M. Gupta; Chelsea Lau; Hina Khan; Justin Liauw; Ana I. Velazquez; Tyiesha Brown; Laura Moliner; Miguel Mosteiro; Pedro Rocha; Mark Evans; Ari Vanderwalde; Andrew Elliott; Jorge Nieva; Gilberto Lopes; Patrick C. Ma; Hossein Borghaei; Matthew Lee; Lauren Young; Raid Aljumaily; Haris Mirza; David J. Kwiatkowski; Roy S. Herbst; Richard A. Flavell; Abdul Rafeh Naqash; Anne C. Chiang
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA; NCT03521154)

LAURA研究完善了奥希替尼治疗EGFR阳性非小细胞肺癌（从IB期到IV期）的拼图：与安慰剂相比，辅助奥希替尼显著改善了不可切除III期EGFR突变非小细胞肺癌的无进展生存期和 CNS进展（LAURA; NCT03521154）

lung cancer targets and therapy
IF0
2025-04-250
OA
Faustine X Luo; Zhaohui Arter; Sai-Hong Ignatius Ou; Misako Nagasaka

研究方向

暂未获取到该数据
S
Sai‐Hong Ignatius Ou
H 指数:92论文数:612被引数:4.7万
A
Ammar Sukari
H 指数:31论文数:292被引数:6,778
Z
Zhaohui Arter
H 指数:7论文数:63被引数:306
D
Danielle Brazel
H 指数:13论文数:60被引数:390
A
Asfar S. Azmi
H 指数:65论文数:455被引数:2.0万
Y
Yoshihisa Yamano
H 指数:41论文数:309被引数:5,267
T
Tomoo Sato
H 指数:30论文数:136被引数:2,744
J
Junji Yamauchi
H 指数:16论文数:63被引数:955
S
Stephen V. Liu
H 指数:55论文数:781被引数:1.9万
N
Natsumi Araya
H 指数:27论文数:85被引数:2,309